SG11201809317VA - Methods for classifying patients with a solid cancer - Google Patents

Methods for classifying patients with a solid cancer

Info

Publication number
SG11201809317VA
SG11201809317VA SG11201809317VA SG11201809317VA SG11201809317VA SG 11201809317V A SG11201809317V A SG 11201809317VA SG 11201809317V A SG11201809317V A SG 11201809317VA SG 11201809317V A SG11201809317V A SG 11201809317VA SG 11201809317V A SG11201809317V A SG 11201809317VA
Authority
SG
Singapore
Prior art keywords
paris
international
solid cancer
medecine
inserm
Prior art date
Application number
SG11201809317VA
Other languages
English (en)
Inventor
Jérôme Galon
Bernhard Mlecnik
Franck Pages
Original Assignee
Inst Nat Sante Rech Med
Univ Sorbonne
Univ Paris Descartes
Univ Paris Diderot Paris 7
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Sorbonne, Univ Paris Descartes, Univ Paris Diderot Paris 7, Hopitaux Paris Assist Publique filed Critical Inst Nat Sante Rech Med
Publication of SG11201809317VA publication Critical patent/SG11201809317VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201809317VA 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer SG11201809317VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305536 2016-05-09
PCT/EP2017/061089 WO2017194556A1 (en) 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer

Publications (1)

Publication Number Publication Date
SG11201809317VA true SG11201809317VA (en) 2018-11-29

Family

ID=56014938

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809317VA SG11201809317VA (en) 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer

Country Status (13)

Country Link
US (1) US20190309369A1 (es)
EP (1) EP3455631B1 (es)
JP (3) JP7281903B2 (es)
KR (1) KR102245021B1 (es)
CN (2) CN109690314B (es)
AU (1) AU2017261685B2 (es)
ES (1) ES2808004T3 (es)
MX (1) MX2018013744A (es)
PL (1) PL3455631T3 (es)
RU (1) RU2745730C2 (es)
SG (1) SG11201809317VA (es)
WO (1) WO2017194556A1 (es)
ZA (1) ZA201807020B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10650911B2 (en) 2017-06-13 2020-05-12 Bostongene Corporation Systems and methods for generating, visualizing and classifying molecular functional profiles
WO2019020556A1 (en) 2017-07-24 2019-01-31 Ventana Medical Systems, Inc. METHODS AND SYSTEMS FOR ASSESSING INFILTRAT OF IMMUNE CELLS IN TUMOR SAMPLES
EP3746790B1 (en) * 2018-01-31 2023-10-04 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iii colorectal cancer
FR3079617B1 (fr) 2018-03-29 2023-12-22 Office National Detude Et De Rech Aerospatiales Onera Methode de detection de cellules presentant au moins une anomalie dans un echantillon cytologique
CN114072676B (zh) * 2019-06-03 2024-07-12 法国国家卫生及研究医学协会 调节治疗方案的方法
CN110988324B (zh) * 2019-11-29 2021-08-24 广州市雷德医学检验实验室有限公司 免疫状态确定系统、方法、装置及存储介质
CN111257563B (zh) * 2020-01-22 2022-08-23 广州泛恩生物科技有限公司 Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途
CN111999503B (zh) * 2020-05-28 2022-05-20 首都医科大学附属北京地坛医院 一组用于预测急性病毒性呼吸道传染病重症化的标志物及其应用和试剂盒
CN113174439B (zh) * 2021-03-30 2022-06-28 中国医学科学院肿瘤医院 一种基于免疫基因对评分体系在预测非小细胞肺癌患者免疫治疗效果中的应用
WO2022229136A1 (en) * 2021-04-27 2022-11-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of lymph node metastasis and/or recurrence of patients suffering from a t1 cancer treated by endoscopic resection
JP2024517986A (ja) * 2021-05-13 2024-04-23 セントリックスバイオ インコーポレイテッド 抗－ＣＤ３００ｃ抗体を利用した併用療法
AU2022447608A1 (en) 2022-03-17 2024-09-26 Assistance Publique - Hôpitaux De Paris Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
WO2023233310A1 (en) * 2022-06-03 2023-12-07 Universita' Degli Studi Di Roma "La Sapienza" Method for determining the prognostic score in patients with metastatic renal carcinoma
CN115747331B (zh) * 2022-09-22 2023-08-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于预测鼻咽癌预后的三级淋巴结构成分标志物组合、系统及应用
TWI826081B (zh) * 2022-10-28 2023-12-11 臺北醫學大學 癌症進展評估方法及其系統
CN117476097B (zh) * 2023-10-25 2024-06-07 中山大学附属第六医院 一种基于三级淋巴结构特征基因的结直肠癌预后和治疗反应预测模型及其构建方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
NZ619527A (en) 2009-04-14 2015-06-26 Nestec Sa Inflammatory bowel disease prognostics
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
JP5970560B2 (ja) * 2012-01-20 2016-08-17 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂ細胞の密度に基づいて、固形癌に苦しむ患者の生存時間を予測するための方法
DE13731071T1 (de) * 2012-06-14 2016-08-18 Assistance Publique Hôpitaux De Paris Verfahren zur Quantifizierung von Immunzellen in Tumorgewebe und dessen Anwendungen
NO2872646T3 (es) * 2012-07-12 2018-01-27
EP3470531A1 (en) * 2012-08-06 2019-04-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for screening patients with a cancer
WO2015007625A1 (en) * 2013-07-15 2015-01-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of survival time of a patient suffering from a solid cancer

Also Published As

Publication number Publication date
JP2019516979A (ja) 2019-06-20
AU2017261685B2 (en) 2023-09-07
BR112018072993A8 (pt) 2022-11-08
CN109690314A (zh) 2019-04-26
ZA201807020B (en) 2020-05-27
EP3455631A1 (en) 2019-03-20
JP2022027788A (ja) 2022-02-14
RU2018143409A3 (es) 2020-06-29
BR112018072993A2 (pt) 2019-03-06
EP3455631B1 (en) 2020-06-24
JP7281903B2 (ja) 2023-05-26
RU2745730C2 (ru) 2021-03-31
JP2024019551A (ja) 2024-02-09
US20190309369A1 (en) 2019-10-10
WO2017194556A1 (en) 2017-11-16
RU2018143409A (ru) 2020-06-10
KR102245021B1 (ko) 2021-04-26
KR20190016025A (ko) 2019-02-15
ES2808004T3 (es) 2021-02-25
CN115198018A (zh) 2022-10-18
MX2018013744A (es) 2019-08-16
AU2017261685A1 (en) 2018-11-15
PL3455631T3 (pl) 2021-04-06
CN109690314B (zh) 2022-08-02

Similar Documents

Publication Publication Date Title
SG11201809317VA (en) Methods for classifying patients with a solid cancer
SG11201809294RA (en) Systems and methods for sensor data analysis through machine learning
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808820QA (en) Methods and kits for the diagnosis and risk stratification of patients with ischemia
SG11201908564RA (en) Devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligase, polymerase, and sequencing reactions
SG11201805835WA (en) Modified oncolytic virus
SG11201804723WA (en) Drowsiness onset detection
SG11201806845VA (en) Moisturizing compositions and uses thereof
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201809606YA (en) Combination therapy for cancer treatment
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201901621VA (en) Development of spinal cord on a microfluidic chip
SG11201810544WA (en) Detecting hematological disorders using cell-free dna in blood
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201408107RA (en) Method for quantifying immune cells in tumoral tissues and its applications
SG11201807972YA (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SG11201810694WA (en) Use of biomarkers in determining susceptibility to disease treatment
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201807501UA (en) Method and system for imaging
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201900253TA (en) Method and system for microbial pharmacogenomics
SG11201808830YA (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201909501TA (en) Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro